The Phase III programme will involve 120 clinical investigative sites across 30 nations, with a significant number already having detected potential PNH patient participants. Omeros is actively ...

The Swiss pharma group said this morning that the top-line results of the APPOINT-PNH trial showed that iptacopan provided “clinically meaningful” increases in haemoglobin levels in patients ...

Apellis Pharma and partner Sobi have won EU approval for their paroxysmal nocturnal haemoglobinuria (PNH) drug pegcetacoplan in Europe, with a more restricted label than in the US. The European ...